Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction - a phase I clinical trial

Vox Sanguinis

Volumn 109, Issue 1, 2015, Pages 44-51

  Thiele, T ^a   Pohler, P ^b   Kohlmann, T ^a   Sumnig A ^a   Aurich, K ^a   Selleng, K ^a   Westphal, A ^a   Bakchoul, T ^a   Petersmann, A ^a   Muller T H ^b   Greinacher, A ^a   Seltsam, A ^b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DRK Blutspendedienst NSTOB   (Germany)

Author keywords

UVC; Pathogen reduction; Phase I clinical trial; Platelet concentrates

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; D DIMER; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IMMUNOGLOBULIN E; LACTATE DEHYDROGENASE; POTASSIUM; SODIUM; THROMBOCYTE ANTIBODY; THROMBOCYTE CONCENTRATE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PHOTOSENSITIZING AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY TEMPERATURE; CALCIUM BLOOD LEVEL; CHILL; CLINICAL CHEMISTRY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; ERYTHROCYTE COUNT; FEVER; FIBRINOGEN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE COUNT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTOPHERESIS; THROMBOEMBOLISM; ULTRAVIOLET C RADIATION; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; RADIATION RESPONSE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; YOUNG ADULT;

ADULT; BLOOD PLATELETS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN E; MALE; PARTIAL THROMBOPLASTIN TIME; PHOTOSENSITIZING AGENTS; PLATELET COUNT; PLATELET TRANSFUSION; PROTHROMBIN TIME; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 84931567550     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12247     Document Type: Article

References (35)

1. Seltsam A, Muller TH: Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162:442-454
2. Mohr H, Steil L, Gravemann U, et al.: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:2612-2624
3. Steinmann E, Gravemann U, Friesland M, et al.: Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products. Transfusion 2013; 53:1010-1018
4. Castro E, Gonzalez LM, Rubio JM, et al.: The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54:2207-2216
5. Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54
6. Cadet J, Sage E, Douki T: Ultraviolet radiation-mediated damage to cellular DNA. Mutat Res 2005; 571:3-17
7. Sinha RP, Hader DP: UV-induced DNA damage and repair: a review. Photochem Photobiol Sci 2002; 1:225-236
8. Pohler P, Muller M, Winkler C, et al.: Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion 2014; Epub ahead of print.
9. Chan HL, Gaffney PR, Waterfield MD, et al.: Proteomic analysis of UVC irradiation-induced damage of plasma proteins: serum amyloid P component as a major target of photolysis. FEBS Lett 2006; 580:3229-3236
10. Davies MJ: Reactive species formed on proteins exposed to singlet oxygen. Photochem Photobiol Sci 2004; 3:17-25
11. Sandgren P, Tolksdorf F, Struff WG, et al.: In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method. Vox Sang 2011; 101:35-43
12. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al.: In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47:653-665
13. AuBuchon JP, Herschel L, Roger J, et al.: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45:1335-1341
14. Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885
15. van Rhenen DJ, Vermeij J, Mayaudon V, et al.: Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79:206-214
16. Pohler P, Lehmann J, Veneruso V, et al.: Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model. Transfusion 2012; 52:2414-2426
17. Bashir S, Cookson P, Wiltshire M, et al.: Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013; 53:990-1000
18. Thiele T, Iuga C, Janetzky S, et al.: Early storage lesions in apheresis platelets are induced by the activation of the integrin alphaIIbbeta(3) and focal adhesion signaling pathways. J Proteomics 2012; 76 Spec No.:297-315
19. Schneider W, Schnaidt M: The platelet adhesion immunofluorescence test: a modification of the platelet suspension immunofluorescence test. Blut 1981; 43:389-392
20. von dem Borne AE, Verheugt FW, Oosterhof F, et al.: A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978; 39:195-207
21. Kohler M, Dittmann J, Legler TJ, et al.: Flow cytometric detection of platelet-reactive antibodies and application in platelet crossmatching. Transfusion 1996; 36:250-255
22. Kiefel V, Santoso S: [Detection of platelet antibodies and antigens] german; in Kiefel V, (ed.): Transfusionsmedizin. Berlin, Heidelberg, Springer, 2010:591-596.
23. Kiefel V, Santoso S, Weisheit M, et al.: Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70:1722-1726
24. Kiefel V: The MAIPA assay and its applications in immunohaematology. Transfus Med 1992; 2:181-188
25. Schrezenmeier H, Walther-Wenke G, Muller TH, et al.: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47:644-652
26. te Boekhorst PA, Beckers EA, Vos MC, et al.: Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005; 45:514-519
27. Heddle NM, Klama L, Singer J, et al.: The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331:625-628
28. Apelseth TO, Hervig TA, Wentzel-Larsen T, et al.: Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006; 46:800-810
29. Cognasse F, Boussoulade F, Chavarin P, et al.: Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46:1184-1189
30. Gravemann U, Pohler P, Mueller TH, et al.: In vitro quality of platelets treated in the THERAFLEX UV-Platelets system is well preserved during storage. Vox Sang 2013; 105(Suppl. 1):134
31. Benjamin RJ, McCullough J, Mintz PD, et al.: Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45:1739-1749
32. North AK, Henschler R, Geisen C, et al.: Evaluation of naturally occurring antibodies to pathogen inactivated red blood cells. Transfusion 2010; 50(Suppl):38A
33. Zavizion B, Purmal A, Chapman J, et al.: Inactivation of mycoplasma species in blood by INACTINE PEN110 process. Transfusion 2004; 44:286-293
34. Hod E, Schwartz J: Platelet transfusion refractoriness. Br J Haematol 2008; 142:348-360
35. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861-1869